Cox model for factors associated with overall survival, relapse-free survival, cumulative incidence of relapse, and nonrelapse mortality
| . | n . | No. of events . | aHR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Overall survival | |||||
| HDAC regimen | |||||
| 123 | 92 | 24 | 1 | — | — |
| 135 | 129 | 46 | 1.40 | 0.85-2.31 | .19 |
| ELN 2010 prognosis | |||||
| Favorable | 104 | 17 | 1 | — | — |
| Intermediate | 88 | 35 | 2.93 | 1.62-5.32 | <.001 |
| Adverse | 26 | 17 | 4.86 | 2.32-10.19 | <.001 |
| Delay between cycle 1 and 2 | |||||
| <40 d | 116 | 26 | 1 | — | — |
| ≥40 d | 77 | 29 | 1.89 | 1.10-3.24 | .02 |
| No cycle 2 | 28 | 15 | 2.05 | 1.02-4.13 | .04 |
| Relapse-free survival | |||||
| HDAC regimen | |||||
| 123 | 92 | 40 | 1 | — | — |
| 135 | 129 | 60 | 1.10 | 0.73-1.64 | .65 |
| ELN 2010 prognosis | |||||
| Favorable | 104 | 29 | 1 | — | — |
| Intermediate | 88 | 52 | 2.64 | 1.67-4.18 | <.001 |
| Adverse | 26 | 18 | 3.55 | 1.97-6.41 | <.001 |
| Cumulative incidence of relapse | |||||
| HDAC regimen | |||||
| 123 | 92 | 34 | 1 | — | — |
| 135 | 129 | 45 | 0.89 | 0.56-1.41 | .63 |
| ELN 2010 prognosis | |||||
| Favorable | 104 | 22 | 1 | — | — |
| Intermediate | 88 | 43 | 2.70 | 1.63-4.51 | <.001 |
| Adverse | 26 | 14 | 3.41 | 1.69-6.90 | .001 |
| Nonrelapse mortality | |||||
| HDAC regimen | |||||
| 123 | 92 | 6 | 1 | — | — |
| 135 | 129 | 15 | 2.27 | 0.85-6.01 | .10 |
| Allogeneic SCT | |||||
| No | 127 | 6 | 1 | — | — |
| Yes | 94 | 15 | 4.95 | 1.84-13.34 | .002 |
| . | n . | No. of events . | aHR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Overall survival | |||||
| HDAC regimen | |||||
| 123 | 92 | 24 | 1 | — | — |
| 135 | 129 | 46 | 1.40 | 0.85-2.31 | .19 |
| ELN 2010 prognosis | |||||
| Favorable | 104 | 17 | 1 | — | — |
| Intermediate | 88 | 35 | 2.93 | 1.62-5.32 | <.001 |
| Adverse | 26 | 17 | 4.86 | 2.32-10.19 | <.001 |
| Delay between cycle 1 and 2 | |||||
| <40 d | 116 | 26 | 1 | — | — |
| ≥40 d | 77 | 29 | 1.89 | 1.10-3.24 | .02 |
| No cycle 2 | 28 | 15 | 2.05 | 1.02-4.13 | .04 |
| Relapse-free survival | |||||
| HDAC regimen | |||||
| 123 | 92 | 40 | 1 | — | — |
| 135 | 129 | 60 | 1.10 | 0.73-1.64 | .65 |
| ELN 2010 prognosis | |||||
| Favorable | 104 | 29 | 1 | — | — |
| Intermediate | 88 | 52 | 2.64 | 1.67-4.18 | <.001 |
| Adverse | 26 | 18 | 3.55 | 1.97-6.41 | <.001 |
| Cumulative incidence of relapse | |||||
| HDAC regimen | |||||
| 123 | 92 | 34 | 1 | — | — |
| 135 | 129 | 45 | 0.89 | 0.56-1.41 | .63 |
| ELN 2010 prognosis | |||||
| Favorable | 104 | 22 | 1 | — | — |
| Intermediate | 88 | 43 | 2.70 | 1.63-4.51 | <.001 |
| Adverse | 26 | 14 | 3.41 | 1.69-6.90 | .001 |
| Nonrelapse mortality | |||||
| HDAC regimen | |||||
| 123 | 92 | 6 | 1 | — | — |
| 135 | 129 | 15 | 2.27 | 0.85-6.01 | .10 |
| Allogeneic SCT | |||||
| No | 127 | 6 | 1 | — | — |
| Yes | 94 | 15 | 4.95 | 1.84-13.34 | .002 |